TG Therapeutics' BRIUMVI Shows Strong Efficacy in Early MS Treatment
Event summary
- TG Therapeutics published post-hoc data from Phase 3 ULTIMATE I & II trials showing BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve MS patients.
- BRIUMVI demonstrated significant improvements in disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in early-treated patients.
- The trials enrolled 1,094 patients with relapsing multiple sclerosis (RMS) across 10 countries.
- BRIUMVI is approved in the U.S. for relapsing forms of MS and in several countries outside the U.S. for RMS with active disease.
The big picture
TG Therapeutics' data reinforces the strategic importance of early, high-efficacy treatment in relapsing multiple sclerosis. The results position BRIUMVI as a potential frontline therapy, competing with established treatments like ocrelizumab and ofatumumab. The biotech sector continues to prioritize high-efficacy, targeted therapies for autoimmune diseases, with BRIUMVI's unique glycoengineering design offering a differentiated approach.
What we're watching
- Market Adoption
- Whether BRIUMVI can sustain its efficacy profile in broader commercial use beyond clinical trials.
- Competitive Positioning
- How TG Therapeutics positions BRIUMVI against existing high-efficacy MS therapies.
- Regulatory Dynamics
- The pace at which regulatory approvals expand for BRIUMVI in additional markets.
Related topics